Portola Pharma

PTLA NASDAQ
26.60
-0.81
-2.96%
Opening 14:06 06/24 EDT
Open
27.40
Prev Close
27.41
High
27.41
Low
26.56
Volume
363.66K
Avg Vol (3M)
1.01M
52 Week High
43.34
52 Week Low
14.81
% Turnover
0.53%
Market Cap
1.81B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Portola Pharma PTLA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
MORE >

Recently

Name
Price
%Change